CDK4/6抑制剂在HR+晚期乳腺癌治疗中的耐药机制及进展后治疗策略
Mechanism of resistance to CDK4/6 inhibitors in HR+advanced breast cancer and subsequent treatment strategies
王蕾 1杨思原 2张季 2聂建云2
作者信息
- 1. 昆明医科大学临床肿瘤学院,昆明 650000
- 2. 云南省肿瘤医院,昆明医科大学第三附属医院,昆明 650000
- 折叠
摘要
细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂联合内分泌治疗已成为激素受体阳性(HR+)、人类表皮生长因子受体-2阴性(HER2-)乳腺癌患者的晚期一线及二线标准治疗方案.尽管CDK4/6抑制剂可实现有效的疾病控制,但对于晚期乳腺癌患者最终仍会因耐药出现疾病进展.目前CDK4/6抑制剂相关耐药机制尚不完全清楚,同时治疗失败后的最佳治疗策略仍是一个亟待解决的问题.本文就CDK4/6抑制剂的潜在耐药机制和后续治疗策略的最新研究进展做一综述.
Abstract
Cyclin-dependent kinase 4/6(CDK4/6)inhibitors plus endocrine therapy have been used as standard first-or second-line treatment for patients with hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer.Although CDK4/6 inhibitors provide excellent control in patients with hormone receptor-positive advanced breast cancer,due to drug resistance cancer progression will eventually occur as treatment proceeds.At present,the resistance mechanism of CDK4/6 inhibitors is not fully understood,and the optimal treatment strategy after failure of CDK4/6 inhibitors remains an urgent problem.This review summarized the potential resistance mechanism and subsequent treatment strategies of CDK4/6 inhibitors.
关键词
细胞周期蛋白依赖性激酶4/6抑制剂/乳腺癌/耐药机制/内分泌治疗Key words
cyclin-dependent kinase 4/6 inhibitor/breast cancer/resistance mechanism/endocrine therapy引用本文复制引用
基金项目
国家自然科学基金(81960479)
国家自然科学基金(81760480)
云南省科技计划(2019FA040)
云南省科技计划(202201AY070001-153)
出版年
2024
NETL
NSTL
万方数据